Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset

Jasper Fuk-Woo Chan, Yanfeng Yao, Man-Lung Yeung, Wei Deng, Linlin Bao, Lilong Jia, Fengdi Li, Chong Xiao, Hong Gao, Pin Yu, Jian-Piao Cai, Hin Chu, Jie Zhou, Honglin Chen, Chuan Qin, Kwok-Yung Yuen, Jasper Fuk-Woo Chan, Yanfeng Yao, Man-Lung Yeung, Wei Deng, Linlin Bao, Lilong Jia, Fengdi Li, Chong Xiao, Hong Gao, Pin Yu, Jian-Piao Cai, Hin Chu, Jie Zhou, Honglin Chen, Chuan Qin, Kwok-Yung Yuen

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe disease in human with an overall case-fatality rate of >35%. Effective antivirals are crucial for improving the clinical outcome of MERS. Although a number of repurposed drugs, convalescent-phase plasma, antiviral peptides, and neutralizing antibodies exhibit anti-MERS-CoV activity in vitro, most are not readily available or have not been evaluated in nonhuman primates. We assessed 3 repurposed drugs with potent in vitro anti-MERS-CoV activity (mycophenolate mofetil [MMF], lopinavir/ritonavir, and interferon-β1b) in common marmosets with severe disease resembling MERS in humans. The lopinavir/ritonavir-treated and interferon-β1b-treated animals had better outcome than the untreated animals, with improved clinical (mean clinical scores ↓50.9%-95.0% and ↓weight loss than the untreated animals), radiological (minimal pulmonary infiltrates), and pathological (mild bronchointerstitial pneumonia) findings, and lower mean viral loads in necropsied lung (↓0.59-1.06 log10 copies/glyceraldehyde 3-phosphate dehydrogenase [GAPDH]; P < .050) and extrapulmonary (↓0.11-1.29 log10 copies/GAPDH; P < .050 in kidney) tissues. In contrast, all MMF-treated animals developed severe and/or fatal disease with higher mean viral loads (↑0.15-0.54 log10 copies/GAPDH) than the untreated animals. The mortality rate at 36 hours postinoculation was 67% (untreated and MMF-treated) versus 0-33% (lopinavir/ritonavir-treated and interferon-β1b-treated). Lopinavir/ritonavir and interferon-β1b alone or in combination should be evaluated in clinical trials. MMF alone may worsen MERS and should not be used.

Keywords: Kaletra; MERS; animal; common marmoset; coronavirus; interferon; lopinavir; mycophenolate; primate; treatment.

© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Figures

Figure 1.
Figure 1.
Schedule of MERS-CoV inoculation, examination, treatment, and necropsy of the common marmosets. aK3 died unexpectedly during anesthesia at 24 hpi, which was likely related to the anesthesia procedure, as common marmosets are very small and fragile. Abbreviations: hpi, hours postinoculation; MERS-CoV, Middle East respiratory syndrome coronavirus; MMF, mycophenolate mofetil.
Figure 2.
Figure 2.
Mean clinical scores of MERS-CoV-infected common marmosets at different time points after virus inoculation. Necropsies of the common marmosets were scheduled at 72 hpi or when the clinical score was ≥35. The number of animals remaining in the experiment is indicated above the bar at each time point. Student t test was performed for comparison when all 3 animals in each group were available. aK3 died unexpectedly during anesthesia at 24 hpi, which was likely related to the anesthesia procedure, as common marmosets are very small and fragile. Abbreviations: hpi, hours postinoculation; MERS-CoV, Middle East respiratory syndrome coronavirus; MMF, mycophenolate mofetil.
Figure 3.
Figure 3.
Serial measurements of body weight of MERS-CoV-infected common marmosets. Mean percentage of weight loss at 24 and 72 hpi, compared with the baseline body weight at 0 hpi. The number of animals remaining in the experiment is indicated above the bar at each time point. aK3 died unexpectedly during anesthesia at 24 hpi, which was likely related to the anesthesia procedure, as common marmosets are very small and fragile. *P < .05. Abbreviations: hpi, hours postinoculation; MERS-CoV, Middle East respiratory syndrome coronavirus; MMF, mycophenolate mofetil.
Figure 4.
Figure 4.
Representative radiological findings and macroscopic pathology of the lungs of MERS-CoV-infected common marmosets. Dorsal-ventral and lateral chest X-rays were performed immediately prior to necropsy. The circles represent areas of interstitial infiltration indicative of pneumonia. The arrows represent gross lesions in the necropsied lungs. A, Untreated common marmoset (U2) at 36 hpi. B, MMF-treated common marmoset (M2) at 36 hpi. C, Lopinavir/ritonavir-treated common marmoset (K1) at 72 hpi. D, Interferon-β1b-treated common marmoset (B2) at 72 hpi. Abbreviations: D, dorsal side; hpi; hours postinoculation; L, left side; MERS-CoV, Middle East respiratory syndrome coronavirus; MMF, mycophenolate mofetil.
Figure 5.
Figure 5.
Representative photomicrographs of histopathology examination and immunohistochemical staining of necropsied lung tissues of MERS-CoV-infected common marmosets. Severe acute bronchointerstitial pneumonia centered on terminal bronchioles, with thickened alveolar interstitium and alveoli being filled with large amount of inflammatory cell infiltrate, edema, and hemorrhage in hematoxylin and eosin (H&E)–stained necropsied lung tissue of untreated (A) and MMF-treated (C) animals collected at 36 hpi (magnification, 100×). Abundant expression of MERS-CoV nucleocapsid protein was detected by mouse anti-MERS-CoV nucleocapsid protein (1:200) antibody (green) overlaid with counterstaining by propidium iodide (red) in the necropsied lung tissues of the untreated (B) and MMF-treated (D) animals (magnification, 100×). These pathological changes were seen extensively in multiple lobes of the necropsied lungs of the untreated and MMF-treated animals. Mild acute bronchointerstitial pneumonia with small amount of inflammatory cell infiltrate and preserved histological architecture in H&E-stained necropsied lung tissue of lopinavir/ritonavir-treated (E) animals collected at 72 hpi (magnification, 100×). Mild to moderate acute bronchointerstitial pneumonia with moderate amount of inflammatory cell infiltrate and hemorrhage in H&E-stained necropsied lung tissue of interferon-β1b-treated (G) animals collected at 72 hpi (magnification, 100×). Small amount of MERS-CoV nucleocapsid protein expression was detected in the necropsied lung tissues of the lopinavir/ritonavir-treated (F) and interferon-β1b-treated (H) animals (magnification, 100×). These pathological changes were only seen in lesions which were confined to 1–2 lobes of the necropsied lungs of the lopinavir/ritonavir-treated and interferon-β1b-treated animals. H&E-stained necropsied lung tissue (I) (magnification, 100×) without MERS-CoV nucleocapsid protein expression (J) of an uninfected control animal. Abbreviations: hpi; hours postinoculation; MERS-CoV, Middle East respiratory syndrome coronavirus; MMF, mycophenolate mofetil.
Figure 6.
Figure 6.
Mean viral loads with standard deviation values in different tissues of MERS-CoV-infected common marmosets collected at the time of necropsy. *P <.05. aTwo of the 3 interferon-β1b-treated animals had undetected viral loads in necropsied kidney tissues, which accounted for a large standard deviation value and apparent lack of statistically significant difference from the mean viral load of the untreated animals. Abbreviations: GAPDH, glyceraldehyde 3-phosphate dehydrogenase; MERS-CoV, Middle East respiratory syndrome coronavirus; MMF, mycophenolate mofetil.

References

    1. Chan JF, To KK, Tse H, Jin DY, Yuen KY. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol 2013; 21:544–55.
    1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367:1814–20.
    1. Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen KY. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev 2015; 28:465–522.
    1. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA et al. . Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013; 13:752–61.
    1. Chan JF, Li KS, To KK, Cheng VC, Chen H, Yuen KY. Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic? J Infect 2012; 65:477–89.
    1. Jiang L, Wang N, Zuo T et al. . Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med 2014; 6:234ra59.
    1. Lu L, Liu Q, Zhu Y et al. . Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun 2014; 5:3067.
    1. Gao J, Lu G, Qi J et al. . Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. J Virol 2013; 87:13134–40.
    1. Du L, Zhao G, Yang Y et al. . A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J Virol 2014; 88:7045–53.
    1. Soo YO, Cheng Y, Wong R et al. . Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004; 10:676–8.
    1. Cheng Y, Wong R, Soo YO et al. . Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24:44–6.
    1. Hung IF, To KK, Lee CK et al. . Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011; 52:447–56.
    1. Yang ZY, Werner HC, Kong WP et al. . Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci USA 2005; 102:797–801.
    1. Weingartl H, Czub M, Czub S et al. . Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol 2004; 78:12672–6.
    1. Chan JF, Chan KH, Kao RY et al. . Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 2013; 67:606–16.
    1. Dyall J, Coleman CM, Hart BJ et al. . Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother 2014; 58:4885–93.
    1. de Wilde AH, Jochmans D, Posthuma CC et al. . Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 2014; 58:4875–84.
    1. Kindrachuk J, Ork B, Hart BJ et al. . Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob Agents Chemother 2015; 59:1088–99.
    1. Liu Q, Xia S, Sun Z et al. . Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry. Antimicrob Agents Chemother 2015; 59:742–4.
    1. Falzarano D, de Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H. Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin. Sci Rep 2013; 3:1686.
    1. Falzarano D, de Wit E, Rasmussen AL et al. . Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 2013; 19:1313–7.
    1. Omrani AS, Saad MM, Baig K et al. . Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis 2014; 14:1090–5.
    1. Falzarano D, de Wit E, Feldmann F et al. . Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLOS Pathog 2014; 10:e1004250.
    1. Chan JF, Choi GK, Tsang AK et al. . Development and evaluation of novel real-time RT-PCR assays with locked nucleic acid probes targeting the leader sequences of human pathogenic coronaviruses. J Clin Microbiol 2015; 53:2722–6.
    1. Zhou J, Chu H, Li C et al. . Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J Infect Dis 2014; 209:1331–42.
    1. Chu H, Zhou J, Wong BH et al. . Middle East respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates both the extrinsic and intrinsic apoptosis pathways [Epub ahead of print] J Infect Dis 2015; 10.1093/infdis/jiv380.
    1. Chan JF, Chan KH, Choi GK et al. . Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J Infect Dis 2013; 207:1743–52.
    1. Chan KH, Chan JF, Tse H et al. . Cross-reactive antibodies in convalescent SARS patients’ sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J Infect 2013; 67:130–40.
    1. Yao Y, Bao L, Deng W et al. . An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus. J Infect Dis 2014; 209:236–42.
    1. Ishimatsu M, Suzuki H, Akiyama H, Miura T, Hayami M, Ido E. Construction of a novel SHIV having an HIV-1-derived protease gene and its infection to rhesus macaques: a useful tool for in vivo efficacy tests of protease inhibitors. Microbes Infect 2007; 9:475–82.
    1. Genentech USA, Inc. Product Information: CellCept®. Accessed 10 June 2015.
    1. Bayer Australia Limited. Product Information: Betaferon® Single use pack drug. Accessed 10 June 2015.
    1. Chu H, Zhou J, Wong BH et al. . Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response. Virology 2014; 454–455:197–205.
    1. Raj VS, Smits SL, Provacia LB et al. . Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus. J Virol 2014; 88:1834–8.
    1. de Wit E, Prescott J, Baseler L et al. . The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. PLOS One 2013; 8:e69127.
    1. Coleman CM, Matthews KL, Goicochea L, Frieman MB. Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. J Gen Virol 2014; 95(Pt 2):408–12.
    1. Zhao J, Li K, Wohlford-Lenane C et al. . Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci USA 2014; 111:4970–5.
    1. Agrawal AS, Garron T, Tao X et al. . Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol 2015; 89:3659–70.
    1. Faure E, Poissy J, Goffard A et al. . Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? PLOS One 2014; 9:e88716.
    1. AlGhamdi M, Mushtaq F, Awn N, Shalhoub S. MERS CoV infection in two renal transplant recipients: case report. Am J Transplant 2015; 15:1101–4.
    1. Rizza SA, Badley AD. HIV protease inhibitors impact on apoptosis. Med Chem 2008; 4:75–9.
    1. Abbott Laboratories. Product Information: Kaletra®. Accessed 10 June 1015.
    1. Chu CM, Cheng VC, Hung IF et al. . Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59:252–6.
    1. Spanakis N, Tsiodras S, Haagmans BL et al. . Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J Antimicrob Agents 2014; 44:528–32.
    1. Lau SK, Lau CC, Chan KH et al. . Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol 2013; 94:2679–90.
    1. de Wilde AH, Raj VS, Oudshoorn D et al. . MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-alpha treatment. J Gen Virol 2013; 94:1749–60.
    1. Hart BJ, Dyall J, Postnikova E et al. . Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol 2014; 95:571–7.
    1. Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis 2014; 20:42–6.
    1. Khalid M, Al Rabiah F, Khan B, Al Mobeireek A, Butt TS, Al Mutairy E. Ribavirin and interferon (IFN)-alpha-2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus (MERS-CoV): a preliminary report of two cases. Antivir Ther 2015; 20:87–91.
    1. Shalhoub S, Farahat F, Al-Jiffri A et al. . IFN-alpha2a or IFN-beta1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother 2015; 70:2129–32.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner